CD8A and melanoma: For instance, CD45RA−CD8+ T cells and CD8+ T effector memory cells in the peripheral blood of melanoma at baseline were positively associated with response to ipilimumab treatment, while CD45RA+ naive CD8+ T cells were more abundant in non-responsive patients (41).